Pregnant or breastfeeding women and fertile patients (men and women) who are not using an effective method of contraception
If fertile, agree to use effective contraception (condom or other barrier methods, oral contraceptives, implantable contraceptives, intrauterine devices) during trial and for up to  days after the completion of study treatment
Women of childbearing potential or fertile men and their partners must be willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for  months following the last dose of MM-.
For fertile men and women, agreement to use effective contraceptive methods duration of study participation and  days after
Female patients who are of childbearing potential and fertile male patients must agree to use an effective form of contraception throughout study participation
Fertile men must also agree to use adequate contraception ( barrier methods or abstinence) during the study and for up to  months after the last dose of study drug
If fertile, willing to use effective birth control methods during the study
Women who are pregnant or breast feeding and fertile patients (men and women) who are not using an effective method of contraception. All patients (men and women) must agree to use an effective method of contraception (if applicable) up to three months after treatment discontinuation.
Pregnant or nursing (fertile patients must use effective contraception during and for up to  months after completion of study treatment)
Fertile males not willing to use contraception
Fertile male and female patients must be willing to use an effective contraceptive method before, during, and for at least  months after the CAR T cell infusion
Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least  days after the last dose of investigational product.
Refusal to use adequate contraception for fertile patients (females and males)
Fertile males not willing to use contraception, as stated above
Fertile male and female patients must be willing to use a contraceptive method before, during, and for at least two months after the T cell infusion
INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Fertile male and female patients must be willing to use a contraceptive method before, during and for at least two months after the T cell infusion
INCLUSION CRITERIA FOR TNBC: Fertile male and female patients must be willing to use a contraceptive method before, during and for at least two months after the T cell infusion
Fertile patients must use effective contraception (condom or other barrier methods, oral contraceptives, implantable contraceptives, intrauterine devices) during and for six months after completion of treatment
In agreement to use an effective barrier method of birth control to avoid pregnancy during the study and for a minimum of  days after study treatment, for all male and female patients who are fertile
Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from randomization through  months after the end of treatment
Fertile men should be willing to use barrier contraception during and for  months after AZD (osimertinib), and fertile women must agree to use adequate contraceptive measures during and for  weeks after AZD (osimertinib); fertile men and women must agree to use adequate contraceptive measures during study therapy and for at least  months after the completion of bevacizumab therapy; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treating physician immediately
A urine pregnancy test will be performed on each fertile premenopausal female prior to entry into the study; patients with childbearing potential must employ effective contraception during the radiation therapy
Pregnant or lactating patients, or fertile female patients with a positive pregnancy test, or fertile female patients unwilling to use adequate contraception during treatment and for  days after completion of treatment
Fertile patients must use effective contraception
For fertile patient (female able to become pregnant or male able to father a child), refusal to use effective contraception during the period of the trial and for  months after the last dose of rucaparib
Refusal to use adequate contraception for fertile patients (females and males) while\n             on treatment and for  weeks after the last dose of rociletinib
For female and male patients who are fertile, agree to use a highly effective form of contraception, as defined by the study protocol.
Women who are pregnant or breast feeding. Fertile patients (men and women) who are not using an effective method of contraception. All patients (men and women) must agree to use an effective contraceptive measure (if applicable) up to six months after treatment discontinuation.
Fertile male patients willing to use adequate contraceptive measures
Female and male patients who are fertile agree to use an effective form of contraception with their sexual partners from registration through  months after the end of treatment
Female patients who are of childbearing potential and fertile male patients must agree to use an effective form of contraception throughout study participation
Fertile subjects must use effective contraception during the course of the study and for  days following withdrawal from the study;
Female and male participants who are fertile must agree to use a highly effective form of contraception with their sexual partners throughout study participation.
Concurrent oral contraceptives/ Fertile patients must use effective barrier contraception;
Fertile women of childbearing potential (WCBP) not using (or refusing to use) adequate methods of contraception as agreed on between her and the consenting investigator; male participants not using (or refusing to use) a condom during intercourse
Fertile patients of either sex who do not use adequate contraceptive methods while on treatment
Fertile patients must use effective contraception
Refusal to use adequate contraception for fertile patients (females and males) for  weeks after the last dose of rociletinib and  weeks after the last dose of erlotinib
Females of childbearing potential with a fertile male sexual partner must agree to employ adequate contraception for the duration of the study.
Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for  days following the last dose of any study therapy). This applies to women of childbearing potential as well as fertile men and their partners
Adequate birth control in fertile patients
Use of effective contraception by fertile males with a female partner of childbearing potential.
In agreement to use an effective barrier method of birth control to avoid pregnancy during the study and for a minimum of  days after study treatment, for all male and female patients who are fertile
Fertile males not willing to use contraception, as stated above
Women of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for  days following the last dose of MM- (an effective form of contraception is an oral contraceptive or a double barrier method)
Fertile Participants must use  effective methods of contraception prior to and through  months after the last dose of the study drug
Fertile patients must use effective contraception
Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for  days following the last dose of any study therapy). This applies to women of childbearing potential as well as fertile men and their partners
Fertile males with female partners who are not willing to use contraception or whose female partners are not using adequate contraceptive protection
Fertile males not willing to use contraception; fertile males must use condom with spermicide; highly effective contraception, as defined above, must be used by both sexes (male patients and their female partners) during study treatment and for  days after the last dose of study medication and should not father a child in this period; a condom is required to be used also by vasectomized men
Fertile patients must use adequate contraception
Male and female patients who are fertile who do not agree to use an effective barrier methods of birth control (i.e. abstinence) to avoid pregnancy while receiving study treatment
Pregnancy or failure to use effective contraception in fertile males or females, and breast-feeding females
Fertile patients must use effective contraception
Fertile patients must agree to use effective contraception during and for  weeks after completion of study
Fertile patients must agree to use effective contraception during and for  weeks after completion of study
